RATIONALE: Mast cell activation syndrome (MCAS) has been increasingly diagnosed. In preparation for a National Institutes of Health workshop, The Mastocytosis Society, Inc. (TMS) conducted a large-scale survey to characterize this population. METHODS: Upon IRB approval, patient/caregiver-reported (medical records not reviewed) data (N 5 1701) were collected through an online Qualtrics survey platform, August 17-25, 2018, from those reporting physician-diagnosed MCAS (n 5 1574) and/or hereditary a-tryptasemia (n 5 61). Data gathered included demographics, diagnoses/comorbidities, diagnostic criteria, symptoms, quality of life (QoL), and perceptions of research and care. RESULTS: Participants' ages ranged from 0-85 (M 5 43.0, SD 5 16.2), 87.8% female; 82.1% received MCAS treatment in the US. Most commonly reported co-occurring conditions were dysautonomia (47.5%) and connective-tissue disorder(s) (41.0%). Of respondents reporting an MCAS diagnosis, 21.5% reported no rise in mast cell mediators, while 24.8% reported elevated baseline serum tryptase, 26.0% N-methylhistamine, and 21.8% prostaglandins. Most used H1 blockers (91.9%), H2 blockers (71.5%), and/or mast-cell stabilizers (55.9%). Moderate/severe symptoms affecting multiple body systems were wide ranging: 45.5% moderately/severely affected by anaphylaxis, 69.4% food-restricted, and 40.1% able to eat < _20 foods. Symptoms impacted QoL, with 87.6% reporting moderate/severe life interruption; 66.1% reporting daily interruption, 84.7% moderately/severely affected by unpredictability of onset, and 48.1% often/very frequently requiring assistance with routine care needs. 68.0% reported fair/poor health, with M 5 17.9 (SD 5 10.6) poor physical health, M 5 11.8 (SD 5 10.2) poor mental health, and M 5 15.1 (SD 5 10.9) activity-limited days in the past month. CONCLUSIONS: Survey data presents a profile of reported MCAS as more chronically disabling than has been widely recognized, with patients in need of improved, more readily available care. Women are significantly less likely than men to be full professors, even after accounting for age, experience, specialty, and measures of research productivity. METHODS: We described sex differences in the Allergy/Immunology workforce using a comprehensive cross-sectional physician database linked to information on physician sex, age, years since residency, specialty, authored publications, National Institutes of Health (NIH) funding, clinical trial investigation, and Medicare reimbursement. We assessed whether there was a sex disparity in academic rank using a multilevel logistic regression model adjusting for factors impacting academic advancement. RESULTS: Among 507 academic allergists, 323 (64%) were men. Female allergists were younger (48y vs 57y, p<0.001), had fewer total (12.5 vs 28.7, p<0.001) and first/last author (8.0 vs. 21.5, p<0.001) average publications, were less likely to have NIH funding (13.0 vs 23.5%, p 5 0.004), were less frequently a clinical trial investigator (10.3% vs 16.1%, p 5 0.07), and generated less average annual Medicare revenue ($44,000 vs 23,000, p 5 0.10). Of 152 (30%) full professors, 126 (83%) were male and 26 (17%) were female. After multivariable adjustment, rates of full professorship among female and male allergists were not significantly different (absolute adjusted difference for female vs male allergists, 6.0%; 95% confidence interval: -8.3%, 20.2%). CONCLUSIONS: Among allergists with U.S. medical school faculty appointments, men and women were similarly likely to be full professor after accounting for factors that influence promotion. However, stark unadjusted differences in promotion and research productivity were identified and warrant additional investigation.

